SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
May 14, 2015 11:03 AM EDT
Leerink Partners analyst Paul Matteis reiterated an Outperform rating and boosted his price target on Sage Therapeutics (NASDAQ: SAGE) to $70.00 (from $54.00) after final phase I/II SAGE-457 data corroborates prior promising results.
Matteis commented, "This morning SAGE reported final... More
May 14, 2015 6:33 AM EDT
SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($0.66), $0.17 worse than the analyst estimate of ($0.49).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
...
More
May 14, 2015 6:18 AM EDT
SAGE Therapeutics (NASDAQ: SAGE) announced that SAGE-547 demonstrated robust activity, with a 77 percent response rate in evaluable patients with super-refractory status epilepticus (SRSE), in a successfully completed Phase 1/2 clinical trial. SAGE-547 also demonstrated favorable tolerability and a benefit-risk profile supporting development in this acutely ill patient population. SRSE is a critical condition in which the brain is in a state of persistent seizure, where patients are placed in a medically induced coma in an attempt to stabilize them and where conventional and approved therapies fail to awaken the patients. Currently, there are no therapies... More
